Safety, tolerability and pharmacokinetics to be evaluated in 22 adults
First participant dosing targeted for December

Peptron, a drug development company, said on Thursday that the Ministry of Food and Drug Safety had approved the investigational new drug (IND) application for Phase 1 clinical trials of PT403, a long-acting obesity treatment based on semaglutide and designed for once-monthly administration using SmartDepot™, its long-acting drug delivery platform technology.


The trial will be conducted at Chungnam National University Hospital in 22 healthy adults. After a single subcutaneous dose of PT403, the trial will evaluate its safety, tolerability and pharmacokinetic (PK) properties.


Peptron corporate logo image. Peptron

Peptron corporate logo image. Peptron

View original image

The trial was designed as a randomized, placebo-controlled, double-blind study. Doses will be escalated in stages across a total of three cohorts, including an active reference group. Administration to each subsequent dose group will be decided after the Safety Review Committee (SRC) reviews the safety and tolerability data from the previous dose group.


PT403 is a long-acting injectable formulation that combines semaglutide, an active ingredient used to treat obesity and diabetes, with Peptron's SmartDepot technology. It is being developed to extend the dosing interval of semaglutide from once a week to once a month.


In recent years, the obesity treatment market has seen continued development of long-acting formulations aimed not only at achieving weight loss but also at improving dosing convenience. Peptron expects that, if PT403 is successfully developed, it could reduce the dosing frequency compared with existing once-weekly formulations and ease the burden of treatment for patients.


In June, Peptron presented preclinical and pilot clinical study results for PT403 at the American Diabetes Association's 2026 Scientific Sessions (ADA 2026). The Phase 1 trial will evaluate the initial safety, tolerability and pharmacokinetic properties of the once-monthly formulation.


The company is carrying out follow-up procedures to prepare for the start of the trial, with the first participant dosing targeted for December. Based on the clinical results, it plans to refine its follow-up development strategy and secure clinical evidence needed for global development.



A Peptron official said, "This IND approval is significant because it marks the entry into full-scale clinical development of a once-monthly semaglutide formulation produced at our own GMP manufacturing facility using SmartDepot technology. We will proceed with the PT403 clinical trial without disruption, systematically evaluate its safety, tolerability and pharmacokinetic properties, and secure clinical evidence for future global development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing